title: Stereotaxic administrations of allogeneic human Vγ9Vδ2 T cells efficiently control the development of human glioblastoma brain tumors.
abstract: Glioblastoma multiforme (GBM) represents the most frequent and deadliest primary brain tumor. Aggressive treatment still fails to eliminate deep brain infiltrative and highly resistant tumor cells. Human Vγ9Vδ2 T cells, the major peripheral blood γδ T cell subset, react against a wide array of tumor cells and represent attractive immune effector T cells for the design of antitumor therapies. This study aims at providing a preclinical rationale for immunotherapies in GBM based on stereotaxic administration of allogeneic human Vγ9Vδ2 T cells. The feasibility and the antitumor efficacy of stereotaxic Vγ9Vδ2 T cell injections have been investigated in orthotopic GBM mice model using selected heterogeneous and invasive primary human GBM cells. Allogeneic human Vγ9Vδ2 T cells survive and patrol for several days within the brain parenchyma following adoptive transfer and can successfully eliminate infiltrative GBM primary cells. These striking observations pave the way for optimized stereotaxic antitumor immunotherapies targeting human allogeneic Vγ9Vδ2 T cells in GBM patients.
authors.affiliation: INSERM, U892, Nantes, France, Univ Nantes, Nantes, France, CNRS, UMR 6299, Nantes, France; LabEx IGO, "Immunotherapy Graft Oncology", Nantes, France.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Jarry
authors.affiliation: INSERM, U892, Nantes, France, Univ Nantes, Nantes, France, CNRS, UMR 6299, Nantes, France; LabEx IGO, "Immunotherapy Graft Oncology", Nantes, France.
authors.forename: Cynthia
authors.initials: C
authors.lastname: Chauvin
authors.affiliation: INSERM, U892, Nantes, France, Univ Nantes, Nantes, France, CNRS, UMR 6299, Nantes, France; LabEx IGO, "Immunotherapy Graft Oncology", Nantes, France.
authors.forename: Noémie
authors.initials: N
authors.lastname: Joalland
authors.affiliation: INSERM, U892, Nantes, France, Univ Nantes, Nantes, France, CNRS, UMR 6299, Nantes, France; LabEx IGO, "Immunotherapy Graft Oncology", Nantes, France.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Léger
authors.affiliation: INSERM, U892, Nantes, France, Univ Nantes, Nantes, France, CNRS, UMR 6299 , Nantes, France.
authors.forename: Sandrine
authors.initials: S
authors.lastname: Minault
authors.affiliation: Cellular and Tissular Imaging Core Facility of Nantes University (MicroPICell), Structure Fédérative de Recherche François Bonamy, University of Nantes , Nantes, France.
authors.forename: Myriam
authors.initials: M
authors.lastname: Robard
authors.affiliation: INSERM, U892, Nantes, France, Univ Nantes, Nantes, France, CNRS, UMR 6299, Nantes, France; LabEx IGO, "Immunotherapy Graft Oncology", Nantes, France.
authors.forename: Marc
authors.initials: M
authors.lastname: Bonneville
authors.affiliation: INSERM, U892, Nantes, France, Univ Nantes, Nantes, France, CNRS, UMR 6299, Nantes, France; LabEx IGO, "Immunotherapy Graft Oncology", Nantes, France; Hotel Dieu, Hôpital de Nantes, Nantes, F-44000, France.
authors.forename: Lisa
authors.initials: L
authors.lastname: Oliver
authors.affiliation: INSERM, U892, Nantes, France, Univ Nantes, Nantes, France, CNRS, UMR 6299, Nantes, France; LabEx IGO, "Immunotherapy Graft Oncology", Nantes, France.
authors.forename: François M
authors.initials: FM
authors.lastname: Vallette
authors.affiliation: INSERM, U892, Nantes, France, Univ Nantes, Nantes, France, CNRS, UMR 6299, Nantes, France; LabEx IGO, "Immunotherapy Graft Oncology", Nantes, France.
authors.forename: Henri
authors.initials: H
authors.lastname: Vié
authors.affiliation: INSERM, U892, Nantes, France, Univ Nantes, Nantes, France, CNRS, UMR 6299, Nantes, France; LabEx IGO, "Immunotherapy Graft Oncology", Nantes, France.
authors.forename: Claire
authors.initials: C
authors.lastname: Pecqueur
authors.affiliation: INSERM, U892, Nantes, France, Univ Nantes, Nantes, France, CNRS, UMR 6299, Nantes, France; LabEx IGO, "Immunotherapy Graft Oncology", Nantes, France.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Scotet
keywords: Aminobisphosphonate; Vγ9Vδ2 T cells; human glioblastoma; immunotherapy; mice model